Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells

Molecular Therapy

Volumn 20, Issue 9, 2012, Pages 1699-1712

  Lévy, Camille ^a,b,c   Amirache, Fouzia ^a,b,c   Costa, Caroline ^a,b,c   Frecha, Cecilia ^a,b,c   Muller, Claude P ^d   Kweder, Hasan ^a   Buckland, Robin ^a,b,c   Cosset, François Loïc ^a,b,c   Verhoeyen, Els ^a,b,c  

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d LABORATOIRE NATIONAL DE SANTÉ   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; LENTIVIRUS VECTOR; MONOCLONAL ANTIBODY; MUTANT PROTEIN; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CONCENTRATION (PARAMETERS); GENOTYPE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOMODULATION; MEASLES VACCINATION; MEASLES VIRUS; NONHUMAN; PROTEIN GLYCOSYLATION; PSEUDOTYPING; SERUM CHARACTERISTICS; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRAL GENETICS; VIRUS INACTIVATION; VIRUS MUTATION;

MEASLES VIRUS;

EID: 84867065255     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.96     Document Type: Article

References (55)

1. Frecha, C, Lévy, C, Cosset, FL and Verhoeyen, E (2010). Advances in the feld of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol Ther 18: 1748-1757.
2. Bonini, C, Ferrari, G, Verzeletti, S, Servida, P, Zappone, E, Ruggieri, L et al. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276: 1719-1724. (Pubitemid 27421983)
3. + T cells. Proc Natl Acad Sci USA 98: 9277-9282. (Pubitemid 32743907)
4. Korin, YD and Zack, JA (1998). Progression to the G1b phase of the cell cycle is required for completion of human immunodefciency virus type 1 reverse transcription in T cells. J Virol 72: 3161-3168. (Pubitemid 28175559)
5. Maurice, M, Verhoeyen, E, Salmon, P, Trono, D, Russell, SJ and Cosset, FL (2002). Effcient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood 99: 2342-2350. (Pubitemid 34525419)
6. Verhoeyen, E, Dardalhon, V, Ducrey-Rundquist, O, Trono, D, Taylor, N and Cosset, FL (2003). IL-7 surface-engineered lentiviral vectors promote survival and effcient gene transfer in resting primary T lymphocytes. Blood 101: 2167-2174. (Pubitemid 36302054)
7. Bovia, F, Salmon, P, Matthes, T, Kvell, K, Nguyen, TH, Werner-Favre, C et al. (2003). Effcient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors. Blood 101: 1727-1733. (Pubitemid 36237567)
8. Serafni, M, Naldini, L and Introna, M (2004). Molecular evidence of ineffcient transduction of proliferating human B lymphocytes by VSV-pseudotyped HIV-1-derived lentivectors. Virology 325: 413-424. (Pubitemid 38902804)
9. + cells derived from human and nonhuman primates. Blood 100: 823-832. (Pubitemid 34832607)
10. Frecha, C, Costa, C, Nègre, D, Gauthier, E, Russell, SJ, Cosset, FL et al. (2008). Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 112: 4843-4852.
11. Frecha, C, Costa, C, Lévy, C, Nègre, D, Russell, SJ, Maisner, A et al. (2009). Effcient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 114: 3173-3180.
12. Lévy, C, Frecha, C, Costa, C, Rachinel, N, Salles, G, Cosset, FL et al. (2010). Lentiviral vectors and transduction of human cancer B cells. Blood 116: 498-500; author reply 500.
13. Frecha, C, Lévy, C, Costa, C, Nègre, D, Amirache, F, Buckland, R et al. (2011). Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors. J Virol 85: 5975-5985.
14. Viana, PO, Ono, E, Miyamoto, M, Salomao, R, Costa-Carvalho, BT, Weckx, LY et al. (2010). Humoral and cellular immune responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen. J Clin Immunol 30: 574-582.
15. Premenko-Lanier, M, Hodge, G, Rota, P, Tamin, A, Bellini, W and McChesney, M (2006). Maternal antibody inhibits both cellular and humoral immunity in response to measles vaccination at birth. Virology 350: 429-432. (Pubitemid 43949419)
16. de Swart, RL, Yüksel, S and Osterhaus, AD (2005). Relative contributions of measles virus hemagglutinin-and fusion protein-specifc serum antibodies to virus neutralization. J Virol 79: 11547-11551. (Pubitemid 41170700)
17. Ertl, OT, Wenz, DC, Bouche, FB, Berbers, GA and Muller, CP (2003). Immunodominant domains of the Measles virus hemagglutinin protein eliciting a neutralizing human B cell response. Arch Virol 148: 2195-2206. (Pubitemid 37506834)
18. Ziegler, D, Fournier, P, Berbers, GA, Steuer, H, Wiesmüller, KH, Fleckenstein, B et al. (1996). Protection against measles virus encephalitis by monoclonal antibodies binding to a cystine loop domain of the H protein mimicked by peptides which are not recognized by maternal antibodies. J Gen Virol 77 (Pt 10): 2479-2489. (Pubitemid 26348370)
19. Pütz, MM, Hoebeke, J, Ammerlaan, W, Schneider, S and Muller, CP (2003). Functional fne-mapping and molecular modeling of a conserved loop epitope of the measles virus hemagglutinin protein. Eur J Biochem 270: 1515-1527. (Pubitemid 36459590)
20. Fournier, P, Brons, NH, Berbers, GA, Wiesmüller, KH, Fleckenstein, BT, Schneider, F et al. (1997). Antibodies to a new linear site at the topographical or functional interface between the haemagglutinin and fusion proteins protect against measles encephalitis. J Gen Virol 78 (Pt 6): 1295-1302. (Pubitemid 27281326)
21. Jin, L, Beard, S, Hunjan, R, Brown, DW and Miller, E (2002). Characterization of measles virus strains causing SSPE: a study of 11 cases. J Neurovirol 8: 335-344. (Pubitemid 34982339)
22. Finsterbusch, T, Wolbert, A, Deitemeier, I, Meyer, K, Mosquera, MM, Mankertz, A et al. (2009). Measles viruses of genotype H1 evade recognition by vaccine-induced neutralizing antibodies targeting the linear haemagglutinin noose epitope. J Gen Virol 90(Pt 11): 2739-2745.
23. Shi, J, Zheng, J, Huang, H, Hu, Y, Bian, J, Xu, D et al. (2011). Measles incidence rate and a phylogenetic study of contemporary genotype H1 measles strains in China: is an improved measles vaccine needed? Virus Genes 43: 319-326.
24. Santibanez, S, Niewiesk, S, Heider, A, Schneider-Schaulies, J, Berbers, GA, Zimmermann, A et al. (2005). Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specifc antibodies? J Gen Virol 86(Pt 2): 365-374. (Pubitemid 40227948)
25. Domínguez, A, Torner, N, Barrabeig, I, Rovira, A, Rius, C, Cayla, J et al.; Working Group for the Study of the Measles Outbreak in Catalonia. (2008). Large outbreak of measles in a community with high vaccination coverage: implications for the vaccination schedule. Clin Infect Dis 47: 1143-1149.
26. Kremer, JR, Brown, KE, Jin, L, Santibanez, S, Shulga, SV, Aboudy, Y et al. (2008). High genetic diversity of measles virus, World Health Organization European Region, 2005-2006. Emerging Infect Dis 14: 107-114.
27. Zhang, Y, Ding, Z, Wang, H, Li, L, Pang, Y, Brown, KE et al. (2010). New measles virus genotype associated with outbreak, China. Emerging Infect Dis 16: 943-947.
28. Leonard, VH, Hodge, G, Reyes-Del Valle, J, McChesney, MB and Cattaneo, R (2010). Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. J Virol 84: 3413-3420.
29. Bouche, FB, Ertl, OT and Muller, CP (2002). Neutralizing B cell response in measles. Viral Immunol 15: 451-471.
30. Massé, N, Ainouze, M, Néel, B, Wild, TF, Buckland, R and Langedijk, JP (2004). Measles virus (MV) hemagglutinin: evidence that attachment sites for MV receptors SLAM and CD46 overlap on the globular head. J Virol 78: 9051-9063. (Pubitemid 39096516)
31. Tahara, M, Takeda, M, Seki, F, Hashiguchi, T and Yanagi, Y (2007). Multiple amino acid substitutions in hemagglutinin are necessary for wild-type measles virus to acquire the ability to use receptor CD46 effciently. J Virol 81: 2564-2572. (Pubitemid 46447022)
32. Szécsi, J, Gabriel, G, Edfeldt, G, Michelet, M, Klenk, HD and Cosset, FL (2009). DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian infuenza A virus. J Infect Dis 200: 181-190.
33. Bordignon, C, Notarangelo, LD, Nobili, N, Ferrari, G, Casorati, G, Panina, P et al. (1995). Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodefcient patients. Science 270: 470-475.
34. Morgan, RA, Dudley, ME, Wunderlich, JR, Hughes, MS, Yang, JC, Sherry, RM et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129. (Pubitemid 44547756)
35. Buchschacher, GL Jr and Wong-Staal, F (2001). Approaches to gene therapy for human immunodefciency virus infection. Hum Gene Ther 12: 1013-1019. (Pubitemid 32692418)
36. Aiuti, A, Vai, S, Mortellaro, A, Casorati, G, Ficara, F, Andolf, G et al. (2002). Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 8: 423-425. (Pubitemid 34546725)
37. Kochenderfer, JN, Wilson, WH, Janik, JE, Dudley, ME, Stetler-Stevenson, M, Feldman, SA et al. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116: 4099-4102.
38. Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
39. Lei, TC and Scott, DW (2005). Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 105: 4865-4870. (Pubitemid 40812408)
40. Stripecke, R, Cardoso, AA, Pepper, KA, Skelton, DC, Yu, XJ, Mascarenhas, L et al. (2000). Lentiviral vectors for effcient delivery of CD80 and granulocyte-macrophage-colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood 96: 1317-1326. (Pubitemid 30658459)
41. Melo, ME, Qian, J, El-Amine, M, Agarwal, RK, Soukhareva, N, Kang, Y et al. (2002). Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol 168: 4788-4795. (Pubitemid 34441388)
42. Luo, XM, Maarschalk, E, O'Connell, RM, Wang, P, Yang, L and Baltimore, D (2009). Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 113: 1422-1431.
43. Recchia, A, Bonini, C, Magnani, Z, Urbinati, F, Sartori, D, Muraro, S et al. (2006). Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 103: 1457-1462. (Pubitemid 43191187)
44. Hu, A, Cattaneo, R, Schwartz, S and Norrby, E (1994). Role of N-linked oligosaccharide chains in the processing and antigenicity of measles virus haemagglutinin protein. J Gen Virol 75 (Pt 5): 1043-1052. (Pubitemid 24143149)
45. Scanlan, CN, Offer, J, Zitzmann, N and Dwek, RA (2007). Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446: 1038-1045. (Pubitemid 46676066)
46. Gnanakaran, S, Bhattacharya, T, Daniels, M, Keele, BF, Hraber, PT, Lapedes, AS et al. (2011). Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog 7: e1002209.
47. Helle, F, Duverlie, G and Dubuisson, J (2011). The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses 3: 1909-1932.
48. Miest, TS, Yaiw, KC, Frenzke, M, Lampe, J, Hudacek, AW, Springfeld, C et al. (2011). Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther 19: 1813-1820.
49. Msaouel, P, Dispenzieri, A and Galanis, E (2009). Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 11: 43-53.
50. Anliker, B, Abel, T, Kneissl, S, Hlavaty, J, Caputi, A, Brynza, J et al. (2010). Specifc gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 7: 929-935.
51. Ageichik, A, Buchholz, CJ and Collins, MK (2011). Lentiviral vectors targeted to MHC II are effective in immunization. Hum Gene Ther 22: 1249-1254.
52. Brandler, S, Ruffe, C, Najburg, V, Frenkiel, MP, Bedouelle, H, Desprès, P et al. (2010). Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 28: 6730-6739.
53. Garrone, P, Fluckiger, AC, Mangeot, PE, Gauthier, E, Dupeyrot-Lacas, P, Mancip, J et al. (2011). A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 3: 94ra71.
54. Guerbois, M, Moris, A, Combredet, C, Najburg, V, Ruffé, C, Février, M et al. (2009). Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology 388: 191-203.
55. Yanagi, Y, Takeda, M, Ohno, S and Seki, F (2006). Measles virus receptors and tropism. Jpn J Infect Dis 59: 1-5.